Gainers YS Biopharma Co., Ltd. (NASDAQ: YS) shares rose 90.3% to $2.36 in pre-market trading after dropping over 7% on Monday. YS Biopharma's PIKA Rabies Vaccine recently received Phase 3 clinical trial approval from Philippines FDA.
/PRNewswire/ -- The human microbiome industry is poised for exponential growth and transformative advancements in the near future. As our understanding of the...
/PRNewswire/ -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT...
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...